ArticleInfection and immunity1999
Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 62 citations in OpenAlex.
- Article
- Surface Structures of Group BMicrobiology spectrum · 2019Review
- Progress toward a group B streptococcal vaccine.Human vaccines & immunotherapeutics · 2018Article
- Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy.Scientific reports · 2017Article
- Distribution of pilus islands and alpha-like protein genes of group B Streptococcus colonized in pregnant women in Beijing, China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
- Group B Streptococcus vaccine: state of the art.Therapeutic advances in vaccines · 2015Review
- Expression of group B protective surface protein (BPS) by invasive and colonizing isolates of group B streptococci.Current microbiology · 2014Article
- Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.Clinical and vaccine immunology : CVI · 2008Article
- Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease.Vaccine · 2008Article
- The frequency of genes encoding three putative group B streptococcal virulence factors among invasive and colonizing isolates.BMC infectious diseases · 2006Article
- Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.Infection and immunity · 2005Article
- Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.Clinical microbiology reviews · 2005Review
- Identification and immunoreactivity of proteins released from Streptococcus agalactiae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2004Article
- Multiplex PCR assay for direct identification of group B streptococcal alpha-protein-like protein genes.Journal of clinical microbiology · 2004Article
- Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.Infection and immunity · 2002Article
- Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein.Infection and immunity · 2002Article
- Molecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes.Journal of clinical microbiology · 2002Article
- Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci.Infection and immunity · 2001Article
- Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.Infection and immunity · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The alpha C protein, a protective surface protein of group B streptococci (GBS), is present in most non-type III GBS strains. Conjugate vaccines composed of the alpha C protein and type III capsular polysaccharide (CPS) might be protective against most GBS infections. In this study, the type III CPS was covalently coupled to full-length, nine-repeat alpha C protein (resulting in III-alpha9r conjugate vaccine) or to two-repeat alpha C protein (resulting in III-alpha2r conjugate vaccine) by reductive amination. Initial experiments with the III-alpha9r vaccine showed that it was poorly immunogenic in mice with respect to both vaccine antigens and was suboptimally efficacious in providing protection in mice against challenge with GBS. Therefore, modified vaccination protocols were used with the III-alpha2r vaccine. Female mice were immunized three times with 0.5, 5, or 20 microgram of the III-alpha2r vaccine with an aluminum hydroxide adjuvant and bred. Ninety-five percent of neonatal mice born to dams immunized with the III-alpha2r vaccine survived challenge with GBS expressing type III CPS, and 60% survived challenge with GBS expressing wild-type (nine-repeat) alpha C protein; 18 and 17%, respectively, of mice in the negative control groups survived (P, <0.0001). These protection levels did not differ significantly from those obtained with the type III CPS-tetanus toxoid conjugate vaccine and the unconjugated two-repeat alpha C protein, which protected 98 and 58% of neonates from infection with GBS expressing type III CPS or the alpha C protein, respectively. Thus, the two-repeat alpha C protein in the vaccine was immunogenic and simultaneously enhanced the immunogenicity of type III CPS. III-alpha vaccines may be alternatives to GBS polysaccharide-tetanus toxoid vaccines, eliciting additional antibodies protective against GBS infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.